NUREMBERG, Germany, March 31 /PRNewswire/ -- NCP engineering GmbH releases version 9.03 of its Secure Enterprise Client. The most important feature is support for the Windows XP operating system in its 64 bit mode. Thereby, NCP is rounding off the client tender with manageable Enterprise variants. The Enterprise VPN solution offers all the functionality that distinguishes an integrated remote-access solution.

REDWOOD CITY, California, March 31 /PRNewswire/ --

Ingenuity Systems, the leading provider of information solutions for life science researchers, announced today that Path Designer, the new pathway publishing tool in IPA 6, was selected as the Best New Product by the scientific community in attendance at the Molecular Medicine Tri-Conference in San Francisco. Path Designer enables researchers to create customized, publication-quality graphics to more clearly communicate their experimental findings and scientific hypotheses. Path Designer offers a distinct advantage to users because the graphics remain interactive, so new information can be added and the original knowledge used to build the pathway remains accessible.

WILTON, Connecticut, March 31 /PRNewswire/ --

Startech Environmental Corp. (OTC Bulletin Board: STHK), a fully reporting, internationally recognized Award-winning Environment and Energy company announced today that "waste2greenenergy (w2ge)," the Company's distributor for the United Kingdom and for the Republic of Poland, intends to install its first Plasma Converter System at a designated facility in Bytom, Poland to process ten-tons of industrial waste per day.

LONDON, March 31 /PRNewswire/ -- The United Bank, Egypt, has announced today that it has completed the implementation of Misys Equation across its entire operations in order to optimise inter-branch communications and reporting. This has already resulted in an improved client service and increased support for its staff across 40 locations in Egypt.

New Jersey Institute of Technolgy math professor Bruce Bukiet is once again opining on outcomes for this season’s Major League Baseball teams. His picks are based on a mathematical model he developed in 2000.

Bukiet’s main areas of research have involved mathematical modeling of physical phenomena, including detonation waves, healing of wounds, and dynamics of human balance. He has also applied mathematical modeling to sports and gambling, in particular for understanding baseball and cricket. Bukiet is an avid Mets fan but no one should hold that against him.

TEL AVIV, Israel, March 31 /PRNewswire/ -- Delek Group Ltd. (TASE: DLEKG) (hereinafter: "Delek Group" or "The Group") announced today its results for the fourth quarter and twelve month periods ending December 31, 2007. The full financial statements in English are available on Delek Group's website at: http://www.delek-group.com

Main Highlights

- Full year net income reached NIS 1.3 billion and NIS 129 million in the fourth quarter

- Strong performance in 2007 in the Israeli fuel sector, US fuel sector and automotive sector

- Declared NIS 64 million dividend for fourth quarter 2007, bringing the year's total to NIS 554 million

LEUVEN, Belgium, March 31 /PRNewswire/ -- Kingfisher Healthcare, a young healthcare company focused on improving patient quality of life, announced today that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market KFH Energy in the United States. The patented, high-tech medical device is designed to alleviate fatigue and pain and has received the CE mark in Europe in September 2007.

DENVER, March 31 /PRNewswire/ --

- Accretive Inlog Acquisition to Extend Global Med's Total Reach to 1,400 Sites in 20 Countries

SUNNYVALE, California, March 31 /PRNewswire/ --

- In Q1 Company Adds 20 New Clients Including Microsoft, Mini, Paramount Pictures, and Toyota, to Worldwide Advertiser Roster

- Also Launches New Production Group to Optimize Creative for Mobile Video Viewing

BASEL, Switzerland, March 31 /PRNewswire/ --

- Epilepsy Drug to be Tested as Treatment for Anxiety

Synosia Therapeutics today announced the start of a multi-site, Phase II clinical trial to evaluate the efficacy of rufinamide (SYN-111), a sodium channel blocker, as a potential treatment for general anxiety disorder.